Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell...
https://pubmed.ncbi.nlm.nih.gov/32749941/Actively Recruiting
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-04-01
590
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are investigating the use of integrated genomic-pathologic classification to guide adjuvant therapy decisions for women with early-stage endometrioid adenocarcinoma of the endometrium who have high-intermediate and intermediate risk features. This phase III randomized trial compares molecular profile-based treatment strategies with standard radiation therapy to better tailor treatment and potentially prevent overtreatment. The study builds on established risk factors and incorporates molecular-genetic information to refine patient care. Participants are assigned to different treatment groups based on their molecular and pathological profiles. One group receives no adjuvant therapy if they have a POLE-mutated profile, vaginal brachytherapy for an intermediate profile, or chemo-radiotherapy for a p53-abnormal profile. The comparator group receives standard treatment consisting of vaginal brachytherapy for intermediate risk cases and external beam pelvic radiotherapy for high-intermediate risk cases. The study treatments involve radiation methods such as vaginal brachytherapy, external beam radiotherapy, and chemotherapy combined with radiation. During the study, women undergo active follow-up including quality of life questionnaires and monitoring for cancer recurrence or progression over 3 to 5 years. Assessments include relapse-free survival, overall survival, adverse events, cancer-specific quality of life, and healthcare costs related to endometrial cancer. The primary outcome focuses on total cancer recurrence within three years. This comprehensive monitoring aims to evaluate the impact of personalized adjuvant therapy on patient outcomes over the study period.
CONDITIONS
PROfiling Based Endometrial Cancer Adjuvant Therapy
X
Xinyu Wang, MD
Y
Yang Li, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
Tongji Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks after surgery until completion of assigned adjuvant therapy
Participants receive adjuvant therapy based on molecular profile or standard radiotherapy recommendations. Treatments include observation, vaginal brachytherapy, external beam radiotherapy, or chemoradiation therapy.
Multiple visits for radiotherapy sessions and chemotherapy cycles as applicable
Duration - Up to 5 years
Participants are monitored for cancer recurrence, survival, adverse events, and quality of life for up to 5 years after treatment.
Regular follow-up visits over 3 to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell...
https://pubmed.ncbi.nlm.nih.gov/32749941/Alicia León-Castillo, Heidi Britton, Melissa K McConechy...
https://pubmed.ncbi.nlm.nih.gov/31829442/Nicole Concin, Xavier Matias-Guiu, Ignace Vergote...
https://pubmed.ncbi.nlm.nih.gov/33397713/Stephanie M de Boer, Melanie E Powell, Linda Mileshkin...
https://pubmed.ncbi.nlm.nih.gov/29449189/B G Wortman, T Bosse, R A Nout...
https://pubmed.ncbi.nlm.nih.gov/30078506/Yang Li, Changkun Zhu, Hongyu Xie...
https://pubmed.ncbi.nlm.nih.gov/36659832/Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
Tongji Hospital
Collaborating Sponsor